Last update Aug. 7, 2026

Linaclotide

Compatible

Safe product and/or breastfeeding is the best option.

A synthetic peptide consisting of 14 amino acids, related to the family of endogenous guanylate peptides. Indicated for moderate to severe constipation associated with irritable bowel syndrome and for chronic idiopathic constipation.

It acts locally in the intestine without being absorbed (EMA 2016). It is metabolised in the intestine to produce its main active metabolite, destyrosin. Both linaclotide and destyrosin are broken down by intestinal enzymes and converted into natural amino acids.

In a multicentre study measuring levels in breast milk, quantities below the limit of quantification were detected (Crittenden 2021).

Its pharmacokinetic data (zero or negligible intestinal absorption with undetectable plasma levels and a high molecular weight) make it highly unlikely that significant quantities will pass into breast milk (EMA 2016).

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Linaclotide in other languages or writings:

Group

Linaclotide belongs to this group or family:

Tradenames

Main tradenames from several countries containing Linaclotide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 1.527 daltons
Theoretical Dose 0.00004 mg/Kg/d
Relative Dose 0.8 %

References

  1. Crittenden N, McGeeney D, Assouline-Dayan Y, Boutros K, Syrzycka M, Bartolini W, Boinpally R, Andrews CN. Linaclotide is not detectable in breast milk of lactating women: An open-label, phase 1 study. J Can Assoc Gastroenterol 2021;4 (Suppl 1):A236. Abstract
  2. EMA. Linaclotida. Ficha técnica. 2016 Full text (in our servers)
  3. EMA. Linaclotide. Drug Summary. 2016 Full text (in our servers)
  4. Müller-Lissner S. Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments. Expert Opin Drug Metab Toxicol. 2013 Abstract

Total visits

23,851

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM